-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
In the high-developed countries, at least one-third of spontaneous (non-traumatic) intracerebral hemorrhage (ICH) in adult survivors of stroke patients receiving oral anti- thrombotic (anticoagulant) drug treatment and prevention of subsequent heart blood vessel disease, even so spontaneous ICH The risk of myocardial infarction and ischemic stroke for survivors is still higher than that of the general population, and the risk of all major hemorrhagic or ischemic cardiovascular events is also higher
Thrombosis prevention heart blood vessel myocardial infarction, stroke, cardiovascular events recently researchers have published more long-term antithrombotic treatment for ICH surviving patient safety the safety of longer-term antithrombotic therapy on survival in patients with ICH researchers recently published
The study was carried out in 122 medical centers in the UK and included 537 patients.
537 patients participated in the study, with an average age of 76.
In the antiplatelet treatment group, 22 people had ICH recurrence (8.
Differences in risk of ICH recurrence between groups
Differences in ICH recurrence risk between groups Differences in ICH recurrence risk between groupsStudies believe that it is safe for patients who survive spontaneous cerebral hemorrhage and stroke to receive antiplatelet drugs for secondary prevention of the risk of major cardiovascular events and will not increase the risk of cerebral hemorrhage recurrence
Spontaneous cerebral hemorrhage and stroke survivors receive antiplatelet drugs for the secondary prevention of major cardiovascular event risks.
Original source:
Rustam Al-Shahi Salman et al.
Effects of Antiplatelet Therapy After Stroke Caused by Intracerebral Hemorrhage Extended Follow-up of the RESTART Randomized Clinical Trial.
JAMA
Leave a message here
